Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain XLRN message board posts where the ticker symbol XLRN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest XLRN SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.07
Acc-no: 0001280600-18-000038 (34 Act)  Size: 51 KB
2018-06-07 001-36065
18887462
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001280600-18-000035 (34 Act)  Size: 68 KB
2018-06-05 001-36065
18881711
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-006662 Size: 6 KB
2018-05-11
8-K  Documents Current report, item 5.02
Acc-no: 0001280600-18-000032 (34 Act)  Size: 30 KB
2018-05-11 001-36065
18827700
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001280600-18-000030 (34 Act)  Size: 4 MB
2018-05-08 001-36065
18814856
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001280600-18-000028 (34 Act)  Size: 129 KB
2018-05-08 001-36065
18814623
8-K  Documents Current report, item 5.02
Acc-no: 0001280600-18-000024 (34 Act)  Size: 28 KB
2018-04-16 001-36065
18756830
DEFA14A  Documents Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Acc-no: 0001280600-18-000022 (34 Act)  Size: 328 KB
2018-04-13 001-36065
18754527
DEF 14A  Documents Other definitive proxy statements
Acc-no: 0001280600-18-000021 (34 Act)  Size: 1 MB
2018-04-13 001-36065
18754513
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001179110-18-005400 Size: 7 KB
2018-04-04
More XLRN SEC Filings


Related news from
Fri, 15 Jun 2018
11:00:00 +0000
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the ongoing Phase 2 trials of luspatercept in patients with beta-thalassemia during an oral presentation at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene. “These results reinforce our enthusiasm for luspatercept’s potential as a safe, efficacious therapy for beta-thalassemia patients over the long term,” said Habib Dable, President and Chief Executive Officer of Acceleron.
Fri, 08 Jun 2018
21:01:00 +0000
Big News Is Fast Approaching for Celgene
A potential blockbuster drug is expected to have pivotal data available soon.
Wed, 06 Jun 2018
18:07:05 +0000
Edited Transcript of XLRN earnings conference call or presentation 8-May-18 9:00pm GMT
Q1 2018 Acceleron Pharma Inc Earnings Call
Mon, 04 Jun 2018
11:00:00 +0000
Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced updated results from the Phase 2 trials of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago. Luspatercept is being developed as part of a global collaboration between Acceleron and Celgene. “The ongoing Phase 2 trials continue to provide important insights into luspatercept’s potential to deliver long-term benefit to thousands of patients with lower-risk MDS,” said Habib Dable, President and Chief Executive Officer of Acceleron.
Thu, 24 May 2018
11:20:00 +0000
Wired News – Acceleron Pharma Commences PULSAR Phase-2 Trial of Sotatercept in Pulmonary Arterial Hypertension
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Acceleron Pharma Inc. (NASDAQ: XLRN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=XLRN as the Company's latest news hit the wire. On May 22, 2018, the Company announced that it has commenced the PULSAR Phase-2 trial of sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), which is a chronic and life-changing disease that can lead to heart failure. Active-Investors.com is currently working on the research report for Aytu BioScience, Inc. (NASDAQ: AYTU), which also belongs to the Healthcare sector as the Company Acceleron Pharma.
Tue, 22 May 2018
11:00:00 +0000
Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced the initiation of the PULSAR Phase 2 trial of sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH), a chronic and life-changing disease that can lead to heart failure. “There is a real need for new treatment options that have the potential to improve survival for PAH patients,” said David Badesch, M.D., the Director of the Pulmonary Hypertension Program at the University of Colorado and Chair of the PULSAR Trial Steering Committee.
Thu, 17 May 2018
13:21:00 +0000
Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver three presentations on luspatercept at the 23rd Congress of the European Hematology Association in Stockholm, Sweden on June 14-17, 2018.
Tue, 08 May 2018
21:11:46 +0000
Acceleron: 1Q Earnings Snapshot
The Cambridge, Massachusetts-based company said it had a loss of 58 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Tue, 08 May 2018
20:01:00 +0000
Acceleron Reports First Quarter 2018 Operating and Financial Results
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2018.
Thu, 03 May 2018
11:55:00 +0000
Factors of Influence in 2018, Key Indicators and Opportunity within Sonic Automotive, STERIS plc, AquaVenture, Senseonics, Acceleron Pharma, and Steelcase — New Research Emphasizes Economic Growth
NEW YORK, May 03, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sonic ...
Wed, 02 May 2018
15:56:09 +0000
Boston biotech entrepreneur Christoph Westphal launches new startup
Westphal has a long track record of co-founding successful drug developers, including Alnylam Pharmaceuticals and Momenta Pharmaceuticals.
Wed, 02 May 2018
11:00:00 +0000
Acceleron to Participate in Two Healthcare Investor Conferences in May
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in May.
Tue, 01 May 2018
11:00:00 +0000
Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the U.S.
Mon, 30 Apr 2018
11:00:00 +0000
Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018
Acceleron Pharma Inc. today announced it will host a webcast and conference call on Tuesday, May 8, 2018 at 5:00 p.m. EDT to discuss its first quarter 2018 operating and financial results.
Thu, 26 Apr 2018
12:00:00 +0000
Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that preliminary results from the ongoing Phase 2 trial of ACE-083 in facioscapulohumeral muscular dystrophy are being presented at the American Academy of Neurology 70th Annual Meeting in Los Angeles, California on April 26, 2018....
Thu, 26 Apr 2018
11:00:00 +0000
Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that two abstracts on lead product candidate luspatercept will be presented at the 2018 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois on June 1-5, 2018.
Sun, 22 Apr 2018
11:15:00 +0000
2 Beta Thalassemia Drugs Are Fast Approaching the Finish Line
New treatments could be coming from Celgene and bluebird bio that reshape how we treat this life-threatening gene disorder.
Tue, 20 Mar 2018
12:30:00 +0000
Report: Developing Opportunities within Heico, Global Medical REIT, Acceleron Pharma, Momenta Pharmaceuticals, Silgan, and Weingarten Realty Investors — Future Expectations, Projections Moving into 2018
NEW YORK, March 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Mon, 12 Mar 2018
11:00:00 +0000
Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH) and the Sotatercept Phase 2 Trial
Acceleron Pharma Inc. , a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it will host an educational webinar on pulmonary arterial hypertension and the Company’s Phase 2 clinical trial of sotatercept in patients with PAH.
Tue, 06 Mar 2018
16:02:22 +0000
High Growth NasdaqGM Stocks For The Day
Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. Below I’veRead More...



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has meant the difference between mediocre and stellar stock performance, peace of mind about retirement and meeting and making wonderful friends. VF is simply the BEST." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards